Skip to content
value.today

Lung Therapeutics, Inc.

🇺🇸 Austin, Texas, USAPharmaceuticalsFounded 2012
Total raised
$70 M
5 rounds on record
Latest round
$10 M
Mar 2022
First round on record
Sep 2014
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Lung Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2022$10 MNo. 5$10 to $50 million

Lung Therapeutics, Inc.: Raise no. 5, Mar 2022

Investors in this round

213 investors had bought by the notice of Apr 4, 2022: 213 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $15 M offered; $5 M still to sell
Smallest investment taken
$15,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$855,525
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Brian Windsor · Executive Officer, Director
  • Charles C. Garner · Executive Officer
  • Aaron G.L. Fletcher · Director
  • William C. Fairey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Newbridge Securities Corporation (CRD 104065) · Boca Raton, FloridaSold in AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, IA, IL, IN, MA, MD, MI, MN, MO, NC, NJ, NY, OH, OK, PA, SC, TX, UT, VA, WA, WI

Signed by Charles Garner, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 4, 2022. Read the notice at the SEC.

equity, optionsSEC
May 2019$39 MNo. 4$10 to $50 million

Lung Therapeutics, Inc.: Raise no. 4, May 2019

Investors in this round

42 investors had bought by the notice of Oct 31, 2019: 42 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$39 M of $39 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • James Brian Windsor · Executive Officer, Director
  • Aaron Brian Fletcher · Director
  • R. A. Session · Director
  • Robert Brian Mills · Director
  • Steven Brian Idell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Brian Windsor, President. Source: SEC Form D and 1 amendment, newest notice filed Oct 31, 2019. Read the notice at the SEC.

equity, optionsSEC
Jun 2018$4 MNo. 3$2 to $10 million

Lung Therapeutics, Inc.: Raise no. 3, Jun 2018

Investors in this round

15 investors had bought by the notice of Jul 26, 2018: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • James Brian Windsor · Executive Officer, Director · President and CEO
  • Aaron Brian Fletcher · Director
  • Jim Brian Mervis · Director
  • Robert Brian Mills · Director
  • Steven Brian Idell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Brian Windsor, President. Source: SEC Form D, newest notice filed Jul 26, 2018. Read the notice at the SEC.

optionsSEC
Mar 2016$14 MNo. 2$10 to $50 million

Lung Therapeutics, Inc.: Raise no. 2, Mar 2016

Investors in this round

17 investors had bought by the notice of May 19, 2017: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • James Brian Windsor · Executive Officer, Director · President and CEO
  • Aaron Brian Fletcher · Director
  • Robert Brian Mills · Director
  • Steven Brian Idell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Brian Windsor, President. Source: SEC Form D and 2 amendments, newest notice filed May 19, 2017. Read the notice at the SEC.

equitySEC
Sep 2014$3 MNo. 1$2 to $10 million

Lung Therapeutics, Inc.: Raise no. 1, Sep 2014

Investors in this round

3 investors had bought by the notice of Sep 30, 2015: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • James Brian Windsor · Executive Officer, Director · President and CEO
  • Aaron Brian Fletcher · Director
  • Joseph Brian Woelkers · Director
  • Robert Brian Mills · Director
  • Steven Brian Idell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Brian Windsor, President. Source: SEC Form D and 1 amendment, newest notice filed Sep 30, 2015. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Lung Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2022).

    SEC Form D · Apr 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2022

That is all the official record says: Lung Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Lung Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 213 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Lung Therapeutics, Inc.
NameRoleNamed in
Brian WindsorExecutive officerApr 2022
Charles C. GarnerExecutive officerApr 2022
James Brian WindsorExecutive officerOct 2019
Aaron G.L. FletcherDirectorApr 2022
Brian WindsorDirectorApr 2022
William C. FaireyDirectorApr 2022
Aaron Brian FletcherDirectorOct 2019
James Brian WindsorDirectorOct 2019
R. A. SessionDirectorOct 2019
Robert Brian MillsDirectorOct 2019
Steven Brian IdellDirectorOct 2019
Jim Brian MervisDirectorJul 2018
Joseph Brian WoelkersDirectorMar 2016